The Inflation Reduction Act (IRA) has faced heavy criticism for redirecting billions from Medicare prescription drug spending to fund green energy initiatives and other Democratic special interests. Less discussed, however, is a provision within the law that unfairly targets small molecule drugs—those in pill, capsule, and tablet form—by subjecting them to price controls four years earlier than biotech drugs. This so-called “pill penalty” threatens medical innovation and patient access to life-saving medications.
